Patents by Inventor Tadashi Makino
Tadashi Makino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050147672Abstract: Tablets quickly disintegrating in the mouth which comprise a bitter drug ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without coating into tablets quickly disintegrating in the mouth.Type: ApplicationFiled: January 18, 2005Publication date: July 7, 2005Inventors: Shinji Ohmori, Yasuo Ohno, Tadashi Makino
-
Publication number: 20040209919Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula 1Type: ApplicationFiled: April 28, 2004Publication date: October 21, 2004Applicant: TAKEDA CHEMICAL INDUSTRIES, LTD.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6749864Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: December 31, 2002Date of Patent: June 15, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Publication number: 20030211155Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula 1Type: ApplicationFiled: January 3, 2003Publication date: November 13, 2003Applicant: TAKEDA CHEMICAL INDUSTRIES, LTD.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Publication number: 20030161879Abstract: Tablets quickly disintegrating in the mouth which comprise a bitter drug ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without coating into tablets quickly disintegrating in the mouth.Type: ApplicationFiled: March 25, 2003Publication date: August 28, 2003Inventors: Shinji Ohmori, Yasuo Ohno, Tadashi Makino
-
Patent number: 6521256Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyanot carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonyl-methyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: February 19, 2002Date of Patent: February 18, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Publication number: 20020137771Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula 1Type: ApplicationFiled: February 19, 2002Publication date: September 26, 2002Applicant: TAKEDA CHEMICAL INDUSTRIES, LTD.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6380234Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: August 8, 2001Date of Patent: April 30, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Publication number: 20020039598Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula 1Type: ApplicationFiled: August 8, 2001Publication date: April 4, 2002Applicant: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6296875Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: June 7, 2000Date of Patent: October 2, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6248357Abstract: A solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and an disintegrants, which exhibits a fast buccal disintegratability and dissolubility.Type: GrantFiled: July 12, 1999Date of Patent: June 19, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasuo Ohno, Tadashi Makino, Junichi Kikuta
-
Patent number: 6235490Abstract: An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20 k hGH) was prepared from an animal immunized with 20 k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20 k hGH, but substantially not to 22 k hGH. The monoclonal antibody was useful for immunoassay of 20 k hGH.Type: GrantFiled: October 29, 1998Date of Patent: May 22, 2001Assignee: Mitsui Chemicals, Inc.Inventors: Ichiro Ikeda, Naoko Kono, Tadashi Makino, Yoshihide Hashimoto
-
Patent number: 6197938Abstract: An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20 k hGH) was prepared from an animal immunized with 20 k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20 k hGH, but substantially not to 22 k hGH. The monoclonal antibody was useful for immunoassay of 20 k hGH.Type: GrantFiled: June 13, 1997Date of Patent: March 6, 2001Assignee: Mitsui Chemicals, IncorporatedInventors: Ichiro Ikeda, Naoko Kono, Tadashi Makino, Yoshihide Hashimoto
-
Patent number: 6123962Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: October 29, 1999Date of Patent: September 26, 2000Assignee: Takeda Chemical Industries, Inc.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 6017560Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonyl methyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: November 19, 1998Date of Patent: January 25, 2000Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 5958453Abstract: A solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and an disintegrants, which exhibits a fast buccal disintegratability and dissolubility.Type: GrantFiled: October 29, 1997Date of Patent: September 28, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasuo Ohno, Tadashi Makino, Junichi Kikuta
-
Patent number: 5879708Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.Type: GrantFiled: February 27, 1997Date of Patent: March 9, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Tetsuro Tabata, Shin-Ichiro Hirai
-
Patent number: 5739165Abstract: A solid pharmaceutical preparation containing 5 to 50% by weight of ibuprofen and 0.1 to 10% by weight of phenylpropionamide or a pharmaceutically acceptable salt thereof which are stabilized. The solid pharmaceutical preparation can be produced by means of granulating with carriers at least one active ingredient, preferably both ingredients separately into the ibuprofen group and the phenylpropanolamine group, and mixing the former with the latter to enhance the stability of the active ingredients. Preferably, in the phenylpropanolamine group, the amount of any reducing sugar is minimized to such an extent as to maintain the stability of the active ingredient. The above pharmaceutical preparation is suitable for a cold remedy, which has a more excellent pharmacological activity based on ibuprofen, less decomposability of phenylpropanolamine and less change of external appearance of the preparation due to low compatibility between phenylpropanolamine and ibuprofen.Type: GrantFiled: July 15, 1994Date of Patent: April 14, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Yoshio Mizukami, Jun-Ichi Kikuta
-
Patent number: 5720974Abstract: A method of producing a fast dissolving tablet comprising compression-molding a composition comprising an active ingredient, a carbohydrate and a barely sufficient amount of water to moisten the surface of particles of said carbohydrate into a tablet form and a fast dissolving tablet obtainable by the method. The active ingredient may for example be a vitamin, a gastrointestinal function conditioning agent or an antipyretic-analgesic-antiinflammatory agent. The carbohydrate includes sugar, starch sugars, lactose, honey, sugar alcohols and tetroses. The amount of water to be added is about 0.3 to 10% by weight. The above fast dissolving tablet has a porous structure with excellent disintegratability and solubility as well as adequate strength.Type: GrantFiled: December 13, 1995Date of Patent: February 24, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Masayuki Yamada, Jun-ichi Kikuta
-
Patent number: 5651997Abstract: An antacid composition comprises, as antacid ingredients, a hydrotalcite and dihydroxyaluminium aminoacetate in such a ratio that the former/the latter equals 30/70 to 90/10 (by weight). The composition may further comprises a readily acting or rapid effecting antacid ingredient such as a magnesium hydroxide in an amount of 10 to 50% by weight. The antacid composition is improved in antacid properties and rapid effecting properties, and is useful as a pharmaceutical composition comprising the antacid composition, a carrier, an additive, an additional pharmaceutically active ingredient and so on. The total amount of the antacid ingredients in the pharmaceutical composition may be 10% by weight or more. The pharmaceutical composition may be formed into a fine granule or a granule with utilizing granulation, or into a tablet by compression-molding.Type: GrantFiled: September 12, 1996Date of Patent: July 29, 1997Assignee: Takeda Chemical Industries, Ltd.Inventors: Tadashi Makino, Shigeyuki Marunaka, Soichiro Imoto